

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 1, 2001, 16:18:24 ; Search time 64.32 Seconds

(Without alignments)
14.885 Million cell updates/sec

Title: US-09-331-631A-32

Perfect score: 76
Sequence: 1 CXXCXXCXXXXXXXXXXCXXCXXC 28

Scoring table: BLOSUM62DX
Gapop 10.0 , Gapext 0.5

Searched: 26485 seqs, 34193795 residues

Total number of hits satisfying chosen parameters: 26485

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

A_Geneseq_36:.*
1: /SIDSL/gcgdata/geneseq/AA1980.DAT:.*
2: /SIDSL/gcgdata/geneseq/AA1981.DAT:.*
3: /SIDSL/gcgdata/geneseq/AA1982.DAT:.*
4: /SIDSL/gcgdata/geneseq/AA1983.DAT:.*
5: /SIDSL/gcgdata/geneseq/AA1984.DAT:.*
6: /SIDSL/gcgdata/geneseq/AA1985.DAT:.*
7: /SIDSL/gcgdata/geneseq/AA1986.DAT:.*
8: /SIDSL/gcgdata/geneseq/AA1987.DAT:.*
9: /SIDSL/gcgdata/geneseq/AA1988.DAT:.*
10: /SIDSL/gcgdata/geneseq/AA1989.DAT:.*
11: /SIDSL/gcgdata/geneseq/AA1990.DAT:.*
12: /SIDSL/gcgdata/geneseq/AA1991.DAT:.*
13: /SIDSL/gcgdata/geneseq/AA1992.DAT:.*
14: /SIDSL/gcgdata/geneseq/AA1993.DAT:.*
15: /SIDSL/gcgdata/geneseq/AA1994.DAT:.*
16: /SIDSL/gcgdata/geneseq/AA1995.DAT:.*
17: /SIDSL/gcgdata/geneseq/AA1996.DAT:.*
18: /SIDSL/gcgdata/geneseq/AA1997.DAT:.*
19: /SIDSL/gcgdata/geneseq/AA1998.DAT:.*
20: /SIDSL/gcgdata/geneseq/AA1999.DAT:.*
21: /SIDSL/gcgdata/geneseq/AA2000.DAT:.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | ID | Description |
|------------|-------|-------------|--------|----|--------------------|
| 1 | 76 | 100.0 | 31 | 21 | Y70731 |
| 2 | 67 | 88.2 | 57 | 21 | Wnt antagonist pro |
| 3 | 67 | 88.2 | 76 | 17 | Crmb metallothione |
| 4 | 67 | 88.2 | 77 | 17 | Hawskbill turtle s |
| 5 | 67 | 88.2 | 77 | 18 | W05265 |
| 6 | 67 | 88.2 | 79 | 21 | Tortoise shell sur |
| 7 | 67 | 88.2 | 109 | 17 | Human 5' EST relat |
| 8 | 67 | 88.2 | 110 | 21 | R84086 |
| 9 | 67 | 88.2 | 115 | 20 | T-Lymphocyte stimu |
| 10 | 67 | 88.2 | 135 | 21 | Human epidermal pr |
| 11 | 67 | 88.2 | 138 | 13 | Drosophila ACP62F |
| 12 | 67 | 88.2 | 149 | 8 | Human secreted pro |
| | | | | | CA455 protein. Ze |
| | | | | | Human insulin rece |

| | | | | | | |
|----|----|------|------|----|--------|--------------------|
| 13 | 67 | 88.2 | 169 | 20 | Y60558 | Human normal blad |
| 14 | 67 | 88.2 | 246 | 19 | W53007 | Mus musculus I-mfa |
| 15 | 67 | 88.2 | 516 | 18 | W15286 | Soluble type I ins |
| 16 | 67 | 88.2 | 560 | 12 | R15051 | Hybrid human insul |
| 17 | 67 | 88.2 | 624 | 11 | R08222 | Extracellular port |
| 18 | 67 | 88.2 | 690 | 19 | W77414 | Human sodium depo |
| 19 | 67 | 88.2 | 782 | 18 | W19763 | Her2-GM-CSF immuno |
| 20 | 67 | 88.2 | 906 | 20 | Y18133 | Human insulin-like |
| 21 | 67 | 88.2 | 934 | 12 | R14402 | Soluble insulin-li |
| 22 | 67 | 88.2 | 934 | 12 | R15048 | Soluble human IGF- |
| 23 | 67 | 88.2 | 935 | 12 | R15050 | Hybrid human insul |
| 24 | 67 | 88.2 | 948 | 12 | R14403 | Extracellular doma |
| 25 | 67 | 88.2 | 948 | 12 | R15049 | Hybrid human insul |
| 26 | 67 | 88.2 | 951 | 21 | Y44993 | DCscf-erbB2EC fu |
| 27 | 67 | 88.2 | 956 | 12 | R15047 | Soluble human insu |
| 28 | 67 | 88.2 | 1214 | 21 | Y79152 | Mouse protein kina |
| 29 | 67 | 88.2 | 1255 | 17 | W01111 | HER-2/neu protein. |
| 30 | 67 | 88.2 | 1255 | 20 | W92406 | Human HER-2/neu on |
| 31 | 67 | 88.2 | 1255 | 21 | Y84780 | Amino acid sequenc |
| 32 | 67 | 88.2 | 1255 | 21 | Y92620 | Human heregulin 2 |
| 33 | 67 | 88.2 | 1337 | 15 | R63123 | IGF-I receptor 943 |
| 34 | 67 | 88.2 | 1337 | 15 | R63124 | IGF-I receptor 950 |
| 35 | 67 | 88.2 | 1337 | 15 | R63125 | IGF-I receptor 957 |
| 36 | 67 | 88.2 | 1337 | 15 | R63126 | IGF-I receptor 100 |
| 37 | 67 | 88.2 | 1367 | 15 | R60795 | Human IGF-1 recept |
| 38 | 67 | 88.2 | 1367 | 15 | R63122 | IGF-1 receptor. H |
| 39 | 67 | 88.2 | 1367 | 17 | R95244 | IGF-1 receptor. H |
| 40 | 67 | 88.2 | 1367 | 17 | R91429 | Human type I insul |
| 41 | 67 | 88.2 | 1367 | 18 | W37692 | Human insulin-like |
| 42 | 67 | 88.2 | 1367 | 19 | W54876 | Homo sapiens IGF-1 |
| 43 | 67 | 88.2 | 1370 | 7 | P60005 | Sequence encoded b |
| 44 | 67 | 88.2 | 1370 | 17 | R91430 | Rat type I insulin |
| 45 | 67 | 88.2 | 1382 | 17 | R77440 | Wild type human in |

ALIGNMENTS

| | |
|--------|---|
| RESULT | 1 |
| ID | Y70731 standard; protein; 31 AA. |
| XX | |
| AC | Y70731; |
| XX | |
| DT | 24-JUL-2000 (first entry) |
| XX | |
| DE | Wnt antagonist protein consensus sequence-1. |
| XX | |
| KW | Wnt antagonist; contraceptive; contraceptive vaccine; oocyte development; |
| KW | female primate contraception; oocyte viability. |
| XX | |
| OS | Synthetic. |
| XX | |
| FH | Key |
| FT | Misc-difference 2 |
| FT | /label= Unknown |
| FT | /note= "Xaa may be 9 amino acids in length; some |
| FT | amino acids may be absent" |
| FT | Misc-difference 4 |
| FT | /label= Unknown |
| FT | /note= "Xaa may be 42 amino acids in length; some |
| FT | amino acids may be absent" |
| FT | Misc-difference 14 |
| FT | /label= Unknown |
| FT | Misc-difference 15 |
| FT | /label= Unknown |
| FT | Misc-difference 16 |
| FT | /label= Unknown |
| FT | Misc-difference 17 |
| FT | /label= Unknown |
| FT | Misc-difference 18 |
| FT | /label= Unknown |
| FT | Misc-difference 19 |

```

FT FT Misc-difference 21 /label= Unknown
FT FT Misc-difference 21 /label= Unknown
FT FT /note= "Xaa may be 10 amino acids in length; some
FT FT amino acids may be absent"
FT FT Misc-difference 23 /label= Unknown
FT FT Misc-difference 24 /label= Unknown
FT FT Misc-difference 25 /label= Unknown
FT FT Misc-difference 27 /label= Unknown
FT FT /label= Unknown
FT FT /note= "Xaa may be 7 amino acids in length; some
FT FT amino acids may be absent"
FT FT Misc-difference 29 /label= Unknown
FT FT /note= "Xaa may be 27 amino acids in length; some
FT FT amino acids may be absent"
FT FT Misc-difference 31 /label= Unknown
FT FT /note= "Xaa may be 13 amino acids in length; some
FT FT amino acids may be absent"
XX PN WO200021555-A1.
XX PD 20-APR-2000.
XX PF 13-OCT-1999; 99WO-US23640.
XX PR 15-OCT-1998; 98US-0104355.
XX PA (HARD ) HARVARD COLLEGE.
XX PI McMahon AP, Parr BA, Vaino S;
XX DR WPI; 2000-317845/27.
XX PT Contraceptive composition for inhibiting oocyte development in a female
XX PT primate comprises a Wnt polypeptide antagonist -
XX PS Claim 12; Page 44; 57pp; English.
XX CC The patent discloses a method of female primate contraception comprising
XX CC administering an antagonist of a Wnt polypeptide, inhibiting oocyte
XX CC development. Wnt polypeptides are useful for promotive maturation of an
XX CC immature oocyte. Wnt polypeptides are also useful for increasing the
XX CC number of mature oocytes and to enhance oocyte viability. The present
XX CC peptide is a consensus sequence of Wnt antagonist which inhibits the
XX CC physiological activity of a Wnt polypeptide. Antagonistic polypeptides
XX CC may contain a cysteine-rich domain.
XX SQ Sequence 31 AA;

Query Match 100.0%; Score 76; DB 21; Length 31;
Best Local Similarity 67.9%; Pred. No. 7.6;
Matches 19; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 1 CXXCXXCXXCXXCXXCXXCXXCXXCXXC 28
DB 3 CXCXCXCXCXCXCXCXCXCXCXCXCXCXCXCXC 30

RESULT 2
ID Y57813 standard; protein: 57 AA.
AC Y57813;
XX
XX
XX 22-MAR-2000 (first entry)
XX
XX Crab metallothionein Class I amino acid sequence.
DE

```

```

XX XX Metallothionein; metal recovery; remediation; heavy metal;
XX KW precious metal; phytochelatin; green algae; Chlamydomonas reinhardtii.
XX OS Eubrachyura.
XX PN WO9960838-A1.
XX PD 02-DEC-1999.
XX PF 28-MAY-1999; 99WO-US12007.
XX PR 28-MAY-1998; 98US-0087374.
XX PA (OHIS ) UNIV OHIO STATE RES FOUND.
XX PI Sayre RT, Traina SJ;
XX DR WPI; 2000-086646/07.
XX PT Novel method for metal recovery, remediation and separation -
XX PS Disclosure; Page 6; 86pp; English.
XX CC The present invention describes a transgenic algal cell (I) of the
XX CC genus Chlamydomonas comprising reproductive genetic material comprising
XX CC a nucleotide sequence capable of expressing chicken type I
XX CC Metallothionein. Also described is a method of removing metal from
XX CC an aqueous medium containing at least one dissolved or suspended
XX CC metal. The transgenic algae are used for the selective separation of
XX CC metals, particularly the separation of precious and desirable metals
XX CC such as gold and uranium, from other metals such as cadmium, zinc and
XX CC copper. The method can be used to facilitate the selective recovery of
XX CC precious and rare metals from mineral sources where aqueous media can
XX CC be used, such as in natural surface water flows, ground water and where
XX CC water may be introduced. The method is suitable for well-drilling,
XX CC soil and water remediation arts, mining fields, and industrial
XX CC engineering. The present sequence represents a Class I metallothionein
XX CC given in the present invention.
XX SQ Sequence 57 AA;

Query Match 88.2%; Score 67; DB 21; Length 57;
Best Local Similarity 18.5%; Pred. No. 66;
Matches 5; Conservative 22; Mismatches 0; Indels 0; Gaps 0;

QY 1 CXXCXXCXXCXXCXXCXXCXXCXXCXXC 27
DB 30 CEGSSGCKCANKEGRKTSKPCSCC 56

RESULT 3
ID W05263 standard; protein: 76 AA.
AC W05263;
XX
XX 18-AUG-1997 (first entry)
XX DE Hawksbill turtle shell-derived 15K protein.
XX KW Family Cheloniidae; hawksbill turtle; marine turtle; 5K protein;
XX KW extraction; dithiothreitol; modifying agent; urea; reducing agent;
XX KW chromatographic separation; high performance liquid chromatography;
XX KW HPLC; anion exchange; keratin; homology.
XX OS Eretmochelys sp.
XX AC JP08269094-A.
XX PN 15-OCT-1996.
XX
XX

```



```

RESULT 6
ID R84086
AC Y64946 standard; Protein: 79 AA.
XX Y64946;
XX
XX
XX 01-FEB-2000 (first entry)
XX
XX
XX Human 5' EST related polypeptide SEQ ID NO:1107.
XX
XX
XX Human: 5' EST; expressed sequence tag; secreted protein; diagnosis;
XX gene therapy; chromosome mapping; upstream regulatory sequence;
XX forensic; location; development; protein synthesis; stability;
XX regulation; identification.
XX
XX Homo sapiens.
XX
XX MO953051-A2.
XX
XX 21-OCT-1999.
XX
XX 09-APR-1999; 99MO-IB00712.
XX
XX 09-APR-1998; 98US-0057719.
XX 28-APR-1998; 98US-0069047.
XX
XX (GEST) GENSET.
XX
XX Dumas Milne Edwards J, Duclert A, Giordano J;
XX WPI: 2000-038446/03.
XX DR N-PSDB: 242560.
XX
XX Novel secreted protein 5' expressed sequence tag sequences used in
XX diagnostic, forensic, gene therapy, and chromosome mapping procedures
XX
XX Claim 3: Page 688; 837pp; English.
XX
XX 242265 to 243075 represent novel 5' expressed sequence tag (EST)
XX sequences, corresponding to human secreted proteins. Y64651 to Y65438
XX represent the EST-related proteins corresponding to Y42265 to Y43052.
XX The 5' ESTs can be used for producing secreted human gene products.
XX They can be used to identify and isolate 5' untranslated regions (UTRs)
XX and upstream regulatory regions which control the location, development
XX stage, rate, and quantity of protein synthesis, as well as stability of
XX mRNA. The ESTs are also useful as probes for chromosome mapping, and to
XX obtain full length cDNA clones. The ESTs can also be used in forensic
XX procedures to identify individuals, or in diagnostic procedures to
XX identify individuals having genetic diseases resulting from abnormal
XX gene expression. The products may also be used in gene therapy protocols.
XX The nucleic acids encoding signal peptides can be used for directing
XX extracellular secretion of a polypeptide or the insertion of a
XX polypeptide into a membrane, or importing a polypeptide into a cell.
XX The proteins encoded by the EST sequences may be useful in treating a
XX variety of human conditions. Secreted proteins have therapeutic value,
XX and the identification of new secreted proteins is valuable. Y42249 to
XX Y42264 and Y64644 to Y64650 represent sequences used in the
XX exemplification of the present invention.
XX
XX Sequence 79 AA:

```

```

Query Match 88.2%; Score 67; DB 21; Length 79;
Best Local Similarity 18.5%; Pred. No. 90;
Matches 5; Conservative 22; Mismatches 0; Indels 0; Gaps 0;

```

```

OY 2 XXXCXXCXXXXXXXXXXCXXCXXCXXC 28
::|::|::|::|::|::|::|::|::|::|
DB 34 hlcvcmcvcvchlcvcmcvcvcascvc 60

```

```

RESULT 7
ID R84086
AC R84086;
XX
XX 28-NOV-1996 (first entry)
XX
XX
XX T-lymphocyte stimulatory protein.
XX
XX
XX E. maxima; T-lymphocyte stimulatory protein; Elmeria; protozoan;
XX coccidiosis; chicken; vaccine; poultry; probe.
XX
XX Elmeria maxima.
XX
XX AU9531720-A.
XX
XX 28-MAR-1996.
XX
XX 15-SEP-1995; 95AU-0031720.
XX
XX 16-SEP-1994; 94EP-0202676.
XX
XX (ALKU) AKZO NOBEL NV.
XX
XX Bumstead JM, Dunn PJJ, Tomley FM, Vermeulen AN;
XX WPI: 1996-210114/22.
XX DR N-PSDB: T14351.
XX
XX DNA encoding Elmeria T-lymphocyte stimulatory protein - used in
XX PT vaccines to protect poultry against coccidiosis, and to develop
XX PT prods. for diagnosis of Elmeria infection
XX
XX Claim 1: Page 46; 59pp; English.
XX
XX This sequence represents E. maxima T-lymphocyte stimulatory protein.
XX CC Elmeria protozoans are the cause of coccidiosis in chickens. The DNA
XX CC encoding this sequence may be attached to a suitable promoter and used
XX CC in a recombinant vector in the production of a vaccine for the protection
XX CC of poultry against coccidiosis. Fragments of this sequence may also
XX CC be used as probes to detect Elmeria-related nucleic acid in tissue.
XX CC Due to poor print quality in the specification, this sequence is a
XX CC "best guess" based on the corresponding DNA sequence.
XX
XX Sequence 109 AA:

```

```

Query Match 88.2%; Score 67; DB 17; Length 109;
Best Local Similarity 18.5%; Pred. No. 1.2e+02;
Matches 5; Conservative 22; Mismatches 0; Indels 0; Gaps 0;

```

```

OY 2 XXXCXXCXXXXXXXXXXCXXCXXCXXC 28
::|::|::|::|::|::|::|::|::|::|
DB 27 kccskccskccskccskccskccskcc 53

```

```

RESULT 8
ID Y44986 standard; Protein: 110 AA.
XX Y44986;
XX
XX
XX 23-MAY-2000 (first entry)
XX
XX
XX Human epidermal protein-3.
XX
XX Human epidermal protein-3; HEP3; epithelial disorder; scabies;
XX dysidrotic eczema; cell proliferative disorder; actinic keratosis;
XX arthritis; autoimmune disorder; inflammatory disorder;
XX acquired immune deficiency syndrome; AIDS; Addison's disease; antiHIV;
XX dermatological; antiarteriosclerotic; antiinflammatory;
XX immunosuppressive.

```

```

Query Match 88.2%; Score 67; DB 17; Length 109;
Best Local Similarity 18.5%; Pred. No. 1.2e+02;
Matches 5; Conservative 22; Mismatches 0; Indels 0; Gaps 0;

```

```

XX OS Homo sapiens.
XX
XX Key Location/Qualifiers
FH Modified-site 21
FT /note= "Potential phosphorylation site"
FT 66.09
FT Modified-site /note= "Glycosaminoglycan attachment site"
XX
XX WO200006727-A2.
XX
XX PD 10-FEB-2000.
XX
XX PF 27-JUL-1999; 99WO-US17107.
XX
XX PR 28-JUL-1998; 98US-0155203.
XX
XX PR 07-DEC-1998; 98US-0155254.
XX
XX PA (INCY-) INCYTE PHARM INC.
XX
XX PI Tang YT, Lal P, Corley NC, Guegler KJ, Patterson C, Baughn MR;
XX PI Yue H;
XX
XX WIPI: 2000-195295/17.
XX
XX DR N-PSDB; Z50579.
XX
XX PT New human epidermal proteins (HEPI-1) to (HEPI-6) useful for the
XX PT diagnosis, treatment and prevention of epithelial, cell proliferative,
XX PT and autoimmune inflammatory disorders
XX
XX PS Claim 1; Fig 1; 82pp; English.
XX
XX CC The present sequence is human epidermal protein-3 (HEPI) expressed in
XX CC proliferating skin tissues. This protein is derived from COLNOR27 cDNA
XX CC library and comprises small proline-rich protein repeats. HEPI-3 shares
XX CC 95% identity with human skin specific protein. Recombinant vectors
XX CC comprising HEPI cDNA are introduced into host cells for protein
XX CC expression. The HEPI proteins are useful for the treatment of epithelial
XX CC disorders, including dyshidrotic eczema and scabies, cell proliferative
XX CC disorders including actinic keratosis and arteriosclerosis, and
XX CC autoimmune/inflammatory disorders like acquired immune deficiency
XX CC syndrome (AIDS) and Addison's disease. Pharmaceutical compositions
XX CC comprising HEPI proteins are useful for treating disorders associated
XX CC with altered HEPI expression.
XX
XX SQ Sequence 110 AA:

```

```

Query Match 88.2%; Score 67; DB 21; Length 110;
Best Local Similarity 18.5%; Pred. No. 1.3e+02;
Matches 5; Conservative 22; Mismatches 0; Indels 0; Gaps 0;

```

```

OY 2 XXCXXXXXXXXXXXXXXXXXCCXXC 28
DB 14 pkcpkctcpkcpkcpkcpkcpkcp 40

```

```

RESULT 9
Y22170
ID Y22170 standard; Protein: 115 AA.
XX
XX Y22170;
XX
XX AC Y22170;
XX
XX DT 09-SEP-1999 (first entry)
XX
XX DE Drosophila Acp62F protein.
XX
XX KW Accessory gland protein; Acp; toxin; insecticide; Drosophila; mating;
XX KW caterpillar; development inhibitor; insect pest; plant protection.
XX
XX OS Drosophila melanogaster.
XX
XX PN WO932149-A1.

```

```

XX XX 01-JUL-1999.
XX PD
XX PF 23-DEC-1998; 98WO-US27603.
XX
XX PR 23-DEC-1997; 97US-0071315.
XX
XX PA (CORR ) CORNELL RES FOUND INC.
XX
XX PI Lung O, Tram K, Wolfner MF;
XX
XX DR WPI: 1999-418671/35.
XX
XX DR N-PSDB; X84363.
XX
XX PT Nucleic acid encoding accessory gland proteins of Drosophila
XX
XX PS Claim 20; Page 12; 89pp; English.
XX
XX CC This sequence is a Drosophila melanogaster accessory gland protein
XX CC (Acp) of the invention. A particular Acp, designated Acp62F, is toxic to
XX CC insects, particularly to Drosophila and caterpillars, and it (or vectors
XX CC that express it) can be used to kill or inhibit development of insect
XX CC pests, for plant protection. More generally detection of Acp's in a
XX CC female fruit fly is indicative of recent mating.
XX
XX SQ Sequence 115 AA:

```

```

Query Match 88.2%; Score 67; DB 20; Length 115;
Best Local Similarity 18.5%; Pred. No. 1.3e+02;
Matches 5; Conservative 22; Mismatches 0; Indels 0; Gaps 0;

```

```

OY 2 XXCXXXXXXXXXXXXXXXXXCCXXC 28
DB 41 tecpvacpceysgngpcvkmcpac 67

```

```

RESULT 10
Y91429
ID Y91429 standard; Protein: 135 AA.
XX
XX AC Y91429;
XX
XX DT 29-JUN-2000 (first entry)
XX
XX DE Human secreted protein sequence encoded by gene 21 SEQ ID NO:150.
XX
XX KW Human; secreted protein; diagnosis; neuroprotective; nootropic;
XX KW neuroleptic; antianemic; cerebroprotective; immunomodulatory;
XX KW anti-microbial; cardiatic; cytostatic; antiinflammatory; haemostatic;
XX KW anticonvulsant; vasotropic; vaccine; gene therapy; anti-sense therapy;
XX KW neural; reproductive; immune disorder; immunodeficiency; infection;
XX KW lymphoma; demyelinating disease; autoimmunity; cancer; inflammation;
XX KW aneurysm; haemorrhage; Alzheimer's disease; Parkinson's disease;
XX KW Huntington's disease; Tourette syndrome; multiple sclerosis; meningitis;
XX KW ischaemia; mania; dementia; obsessive compulsive disorder;
XX KW viral prolylaxia; developmental disorder; sexually-linked disorder;
XX KW cardiovascular disorder; food additive; preservative.
XX
XX OS Homo sapiens.
XX
XX PN WO200011014-A1.
XX
XX PD 02-MAR-2000.
XX
XX PF 24-AUG-1999; 99WO-US19330.
XX
XX PR 25-AUG-1998; 98US-0097917.
XX
XX PR 31-AUG-1998; 98US-0096634.
XX
XX PA (HUMA-) HUMAN GENOME SCI INC.
XX
XX PI Moore PA, Ruben SM, Olsen HS, Shi Y, Kosen CA, Florence KA;

```

```

PI Soppet DR, Lafleur DW, Endress GA, Ebner R, Komatsoulis G;
PR Duan RJ;
XX WPT: 2000-224656/19.
XX
XX Novel secreted proteins and corresponding DNA molecules that can be
DR used to prevent, treat and diagnose disease in humans, for example,
PR Alzheimer's, cancer, and immune disorders -
XX
XX Disclosure: Page 403; 416pp: English.
PS
CC The polynucleotide sequences given in A26281 to A26336 encode the human
XX secreted proteins given in Y91346 to Y91449. The human secreted proteins
CC can have activities based on the tissues and cells they are expressed in.
CC Examples of the activities are: neuroprotective; nootropic; neuroleptic;
CC antitactic; cerebroprotective; immunomodulatory; anti-microbial; cardiatic;
CC vasostatic; antiinflammatory; haemostatic; anticoagulant; and
CC vasotropic. The polynucleotides and proteins may be used to prevent,
CC treat or ameliorate a medical condition, e.g. by protein or gene therapy.
CC Conditions treatable by the proteins of the invention include neural,
CC reproductive, or immune disorders, especially immunodeficiency,
CC infection, lymphomas, demyelinating diseases, auto-immunities, cancer,
CC general microbial infection, inflammation, aneurysms and haemorrhages.
CC Specific examples include: Alzheimer's disease; Parkinson's;
CC Huntington's; Tourette syndrome; multiple sclerosis; meningitis;
CC ischaemia; prostate cancer; mania; dementia; obsessive compulsive
CC disorder and viral prophylaxis. The polynucleotides and proteins can also
CC be used in the detection of disorders associated with the function of the
CC protein, for example, the detection of developmental disorders,
CC sexually-linked disorders, or disorders of the cardiovascular system.
CC They may also be used as food additives or preservatives. A26272 to
CC A26280 and Y91345 are sequences used in the exemplification of the
CC present invention.
XX
SQ Sequence 135 AA;

```

```

XX  MPI. 1992-300043/36.
DR  N-PSDB; Q27949.
XX  Author-specific promoters - for control of expression of
PT  male-sterile or male fertility-restorer DNA in monocots e.g.
PT  wheat or corn
XX
PS  Disclosure: Page 31-33; 44pp; English.
CC  The sequence given is encoded by a male flower-specific cDNA sequence
CC  isolated from corn. The cDNA sequence was isolated by using probes
CC  based on the gene core region. The cDNA sequence can be used in a
CC  foreign, chimeric DNA sequence containing a male-sterility DNA or a
CC  male-fertility restorer DNA under the transcriptional control of the
CC  promoter sequence. This vector can be used to transform the nuclear
CC  genome of a cell of a plant.
XX
SQ  Sequence 138 AA:

Query Match      88.2%; Score 67; DB 13; Length 138;
Best Local Similarity 18.5%; Pred. No. 1.5e+02;
Matches 5; Conservative 22; Mismatches 0; Indels 0; Gaps 0.

OY  2 XXXCXXCXXXXXXXXXXCXXCXXCXXC 28
    ::::::::::::::::::::::::::::
DB  112 micgkgtlsahskcaakctkscvptc 138

RESULT 12
P70057 P70057 standard; protein: 149 AA.
XX
AC P70057;
XX
DT 27-JAN-1991 (first entry)
DE Human insulin receptor.
XX
KW Furin; insulin receptor; tumor diagnosis.
XX
OS Homo sapiens.
XX
PN EP246709-A.
XX
PD 25-NOV-1987.
XX
PF 19-MAY-1987; 87EP-0200940.
XX
PR 20-MAY-1986; 86NL-0001271.
XX
PA (UYKA-) KATHOLIEKE UNIV.
XX
PI Van de Ven WJM;
PI Roentoeck AJM;
PI Schalken JA;
XX
DR MPI. 1987-328946/47.
XX
PT Recombinant DNA containing the fur gene - used for producing furin
PT protein and antibodies and as a diagnostic aid in the detection of
PT tumours.
XX
PS Disclosure: Fig 10; 24pp; English.
CC The sequence of the human insulin receptor is provided for
CC comparison with the cysteine-rich region of furin. Furin
CC is strongly expressed in specific types of tumors and
CC labelled RNA or DNA probes of the fur gene and antibodies
CC against furin can be used for diagnostic purposes.
CC (See also N70061, N70062, N70060, P70056 and P70058)
XX

```


